Abstract
Purpose :
To assess morphometric and functional changes in patients with vision loss due to CNV related to causes other than AMD and myopia
Methods :
Retrospective review of patients with CNV not related to AMD or myopia managed with intravitreal antiangiogenic therapies between March 2011 and August 2016 at the Unit of Macula of the Hospital La Fe (Valencia, Spain). Information regarding best corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), qualitative changes in the OCT scans (intraretinal fluid -IRF- and subretinal fluid -SRF-) and number of intravitreal injections was obtained from the medical records.
Results :
Nineteen patients were included (mean age: 47.4 years; 68.4% female gender). The underlying diagnosis included multifocal choroiditis (n=6); birdshot chorioretinopathy (n=1); idiopathic macular telangiectasia type 2 (n=1); angioid streaks (n=3); adult onset foveomacular vitelliform dystrophy (n=2); and idiopathic CNV (n=5). The mean follow-up period was 32.4 months [13.0-44.3], with a mean number of intravitreal antiangiogenic drugs injections of 7.6 [1-21]. Mean BCVA improved from 0.37 +/- 0.3 logMAR to 0.15 +/-0.3 logMAR (p<0.001). CRT decrease correlated to BCVA improvement (r=0.83; p<0.001). IRF persisted in 57.9% of cases at the final follow-up visit, whereas SRF persisted in 36.9%. SFCT of eyes with CNV was significantly increased compared to the fellow eyes at baseline, and decreased through the follow-up.
Conclusions :
Intravitreal injections of antiangiogenic drugs may achieve positive functional and anatomical outcomes in eyes with CNV related to causes other than AMD or myopia. SFCT was significantly increased at baseline compared to the fellow eyes.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.